Methods of treatment using a dexmedetomidine premix formulation
The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
1. A method of providing analgesia to a patient in need thereof, the method comprising administering to the patient an effective amount of a composition, wherein the compositon comprises dexmedetomidine or a pharmaceutically acceptable salt thereof at a concentration of about 0.005 to about 50 μg/mL, wherein the composition is a ready to use liquid pharmaceutical composition for parenteral administration to the patient disposed within a sealed glass container.
2. The method of claim 1 , wherein the dexmedetomidine or pharmaceutically acceptable salt thereof is at a concentration of about 0.05 to about 15 ug/mL.
3. The method of claim 1 , wherein the dexmedetomidine or pharmaceutically acceptable salt thereof is at a concentration of about 0.5 to about 10 ug/mL.
4. The method of claim 1 , wherein the dexmedetomidine or pharmaceutically acceptable salt thereof is at a concentration of about 1 to about 7 ug/mL.
5. The method of claim 1 , wherein the dexmedetomidine or pharmaceutically acceptable salt thereof is at a concentration of about 4 ug/mL.
6. The method of claim 1 , wherein the composition is administered perioperatively.
7. The method of claim 6 , wherein the composition is administered before or after surgery.
8. The method of claim 1 , wherein the composition is administered to the patient in an intensive care unit.
9. The method of claim 1 , wherein the patient is non-ventilated or intubated.
10. The method of claim 1 , wherein the patient is critically ill.
11. The method of claim 1 , wherein the composition is administered by an intravenous infusion.
12. The method of claim 1 , wherein the composition is administered as an anxiolytic.
13. The method of claim 1 , wherein the composition is administered as an adjunct to an anesthetic.
14. The method of claim 1 , wherein the composition is administered as a sedative.
15. The method of claim 1 , wherein the composition is administered as an anti-hypertensive agent.